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Abstract: The reproducibility of mass spectrometry (MS) data collected using surface enhanced laser desorption/ionization-time of flight   (SELDI-TOF) 
has been questioned. This investigation was designed to test the reproducibility of SELDI data collected over time by multiple users and instru-
ments. Five laboratories prepared arrays once every week for six weeks. Spectra were collected on separate instruments in the individual   laboratories. 
  Additionally, all of the arrays produced each week were rescanned on a single instrument in one laboratory. Lab-to-lab and array-to-array variability 
in alignment parameters were larger than the variability attributable to running samples during different weeks. The coefficient of variance (CV) in 
spectrum intensity ranged from 25% at baseline, to 80% in the matrix noise region, to about 50% during the exponential drop from the   maximum 
matrix noise. Before normalization, the median CV of the peak heights was 72% and reduced to about 20% after normalization.   Additionally, for the 
spectra from a common instrument, the CV ranged from 5% at baseline, to 50% in the matrix noise region, to 20% during the drop from the maximum 
matrix noise. Normalization reduced the variability in peak heights to about 18%. With proper processing methods, SELDI instruments produce spectra 
containing large numbers of reproducibly located peaks, with consistent heights.
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Introduction
Since  its  introduction  onto  the  biotech  market  in 
2000,  researchers  have  used  and  continue  to  use 
the SELDI-TOF MS-based ProteinChip System for 
  discovery of cancer-related biomarkers in addition 
to   markers of other disease states such as peripheral 
arterial    disease,  thrombotic  thrombocytopenic  pur-
pura, sickle cell disease, cystic fibrosis, hereditary 
  thrombophilia,  Peyronie  disease  and  Alzheimer 
disease.1–7   Numerous examples of potential biomark-
ers for cancer detection,8–19 prognosis,20–22 response to 
therapy23–25 or survival26 identified using the SELDI 
platform continue to appear in the literature. Ques-
tions about the reproducibility of MS data collected 
using a SELDI system have, however, led to uncer-
tainty about the overall usefulness of this technol-
ogy in cancer proteomics research. One of the most 
thorough  evaluations  of  SELDI-  TOF-discovered 
biomarkers,  the  EDRN  prostate  cancer  biomarker 
study,27,28  was  launched  following  demonstration 
of    acceptable  reproducibility  across  laboratories.29 
In the end, SELDI-discovered biomarkers appeared 
to lack diagnostic value for prostate cancer after a 
second  stage  of  validation  failed  to  separate  can-
cer  from  normal  controls.  The  authors  pointed  to 
  possible flaws in study design such as the use of un-
fractionated serum. In support of such reservations, 
other investigators have suggested that some form of 
fractionation of serum or plasma will be required to 
detect consistently the more interesting, low abun-
dance proteins.30–32
In addition to the use of patient blood, other cancer 
biomarker studies have been generated on the SELDI 
platform using such samples as urine, saliva, nipple 
aspirate fluid (NAF), pancreatic juice, tissue lysates 
and cell culture.33–39 Whatever the sample source or 
extent of preparation prior to analysis, it is important 
to  remember  that  in  designing  experiments  using 
  biological samples, both pre-analytical and analytical 
factors contribute to the variability in measurements 
made  using  any  assay  method,  including  SELDI-
TOF-MS. These factors include inter-individual bio-
logical differences, differences in sample handling, 
differences in protocol design and execution, and dif-
ferences in instrument performance.
Studies  designed  specifically  to  assess  SELDI 
peak reproducibility have consistently reported coef-
ficient of variation (CV’s) in the 30% range, both on 
an  intra-laboratory  and  inter-laboratory  basis.29,40–42 
A number of studies have attempted to ascertain   factors 
that impact variability. Liggett et al   determined that 
variance was greater between separate arrays (biochips) 
than between spots on a single array and suggested 
this variability might be decreased by improving the 
array manufacturing and handling processes.43 Some 
of these studies have explored pre-analytical factors. 
For example, Timms et al explored various types of 
tubes for blood collection, clotting time, and storage 
time on peak profiles.41 The authors concluded that 
the most stringent and the least stringent conditions 
had the least variability,   presumably because the most 
stringent condition controls proteolysis and the least 
stringent  condition  allows  for  proteolysis  to  reach 
completion. Understanding the relative contribution 
of these factors to overall variability should permit 
researchers to better design and execute clinical pro-
teomics studies.
This  investigation,  conducted  in  five    individual 
laboratories at the University of Texas M.D. Anderson 
Cancer Center, was designed to test the   reproducibility 
of SELDI data collected over time by multiple users 
and  instruments.  Our  focus  was  to  test  the  effect 
of  consistent  sample  handling,  preparation,  and  in 
  particular, data acquisition among participating labo-
ratories on the variability of data obtained over time. 
Arrays were manually prepared with a fresh serum 
sample weekly for six consecutive weeks in each lab-
oratory. All laboratories used aliquots from the same 
batch of serum. Mass spectra were collected on sepa-
rate instruments in the individual laboratories. In addi-
tion, all arrays were read on a common instrument in 
the same laboratory every week. In this report, we 
describe  the  analysis  of  the  spectra  collected  over 
time on individual instruments as well as on the com-
mon  instrument.  The  experimental  design  and  the 
methods for assessing reproducibility are applicable 
to other forms of MS used in protein profiling, not 
just SELDI.
Materials and Methods
Instruments
All five laboratories followed a standard operating 
procedure  (SOP).  Briefly,  five  ProteinChip  System 
instruments  (Ciphergen  Biosystems,  Inc.)  located 
in separate laboratories and operated by the respec-
tive laboratory personnel were used. Four were the reproducibility of SeLDI spectra
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PBSII series; one was a PBSIIc. Before the study, 
each instrument was checked by a service engineer 
and adjusted to   perform at individual optimum levels. 
Instruments  were  not  engineered  to  be  ‘matched’ 
for identical data production. Heat Inactivated Fetal 
Bovine Serum (FBS) (Invitrogen-Life   Technologies) 
was  used  as  the  quality  control  sample  for  all 
  laboratories. Two commercially available (Ciphergen 
  Biosystems, Inc.) cationic exchange arrays (CM10) 
were  prepared  manually  with  samples  once  every 
week for six weeks. CM10 arrays were pre-wetted 
twice with binding buffer and 50 µl of a denatured 
serum sample was added to each spot of the array 
in a bioprocessor. The arrays were incubated with 
sample for 30 min with shaking. The model of shaker 
  varied across laboratories. After incubation, each spot 
was washed three times with binding buffer and then 
quickly two times with water. After air-drying, 1 µl 
of sinapinic acid (Ciphergen Biosystems) was applied 
twice.  Before  reading  the  prepared  arrays,  a  new 
calibration curve was created from 12230, 16951 and 
29023 Daltons each week from All in One Protein II   
mass calibrants (Ciphergen Biosystems),   prepared by 
each user according to the manufacturer’s   instructions. 
The spot protocol for calibration curve data collection 
was set identically on each instrument for parameters 
of lag time, warming shots, mass optimization window, 
and number of total shots averaged (Supplementary 
SOP file). The PBSIIc allows for setting of a deflec-
tor mass and was set at 1000   Daltons. However, the 
sample-containing arrays were read using settings for 
low mass data collection that varied in laser inten-
sity and detector sensitivity as was   optimal for each 
instrument.
Study design 
Each week for six weeks, investigators in five laborato-
ries manually prepared protein samples from aliquots 
of the same batch of serum. Samples were applied to 
all spots of two CM10   ProteinChip arrays (16 spots 
per  lab  per  week).    Spectra  were  collected  on  the 
instruments in the individual laboratories from each 
spot using low intensity laser settings. In addition, we 
collected another set of spectra by rescanning all spots 
at low intensity on a common (PBCIIc) instrument in 
the same laboratory every week. Because of equip-
ment failure, one laboratory produced no data during 
two weeks of the study. Because of a clerical error, 
data from one chip, along with three additional spots, 
from another laboratory were not scanned on the com-
mon instrument. As a result, we collected 445 spectra 
from individual instruments and 440 spectra on the 
common instrument.
Processing spectra
Spectra were collected with a digitizer rate of  250 MHz, 
which was dictated by the hardware; each intensity 
represents  the  number  of  ions  hitting  the  detector 
  during a period of τ = 4 nanoseconds. Raw spectra 
were aligned by the transformation t′ =   Multiplier* 
t +   Offset. The average of all raw   spectra was the 
base  spectrum  to  which  all  others  were  aligned. 
We computed 4 different shifts that maximized the 
cross-correlation between baseline-  corrected   spectra 
within 4 separate small time windows that cover 4 
dominant  peaks  in  the  mean  spectrum  (Fig.  S4A 
of  Supporting  Information).  To  perform  baseline 
removal, we applied an undecimated discrete wave-
let  transform  (UDWT)  with  a  threshold  of  500  to 
each spectrum (2000 for the average raw spectrum), 
subtracted the smooth part, and used the residuals as 
the baseline-corrected spectrum.44 By least squares 
approximation, we computed the values of Multiplier 
and Offset for which the transformation above yields 
the best approximation of the four shifts.
The spectra scanned on the common instrument 
were collected at 500 MHz (τ = 2 nanoseconds), which 
was  again  dictated  by  the  hardware.  Raw    spectra 
were aligned by shifting by a small integer multiple 
of τ; the “multiplier” term, which   represents physical 
differences  between  instruments,  was  unnecessary 
for data scanned on a single instrument. An arbitrary 
spectrum produced during week 1 from the first labo-
ratory was the base spectrum. We baseline-corrected 
each  spectrum  (as  above)  and  computed  the  shift 
that  maximized  the  cross-correlation  between  cor-
rected spectra, using MATLAB version 7.0.1 (The 
Mathworks, Natick MA).
We  used  the  UDWT  with  a  threshold  of  20  to 
denoise  the  mean  spectrum,  using  the  Cromwell 
software package;44,45 local maxima in the denoised 
mean  spectrum  were  identified  as  peaks.  Intervals 
containing the peaks and the location of the maxima 
within  intervals  were  recorded.  Peak  heights  were 
quantified as the difference between the maxima and 
minima in the corresponding interval.Diao et al
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Linear models were fit in R version 2.7.1, using 
the functions lm and lme.46,47
Results
Alignment variability across instruments
All  spectra  were  aligned  as  described  above.  For 
all  but  13  of  the  445  spectra,  the  offsets  ranged 
between −10τ and +20τ. The 13 unusual spectra had 
offsets between 115τ and 120τ; they were produced in 
the same lab during the same week. These 13 spectra 
had poor alignment for t , 30 µs (Figs. S6 and S7 
of   Supporting Information); they were excluded from 
further analysis. For the spectra scanned on the com-
mon  instrument,  the  offsets  ranged  between  −10τ 
and  +10τ  for  all  but  3  of  the  440  spectra.  These 
3 spectra had offsets of −42τ, −28τ, and +45τ; they 
were low quality by visual inspection and excluded.
We hypothesized that spot position on the array 
might affect the offset (Figs. S2 and S14 of Supporting 
Information), for two reasons. First, Peaks software 
(Ciphergen Biosystems) version 3.1.1 included a “spot 
correction factor” to adjust for the different positions 
of different spots relative to the laser and drift tube 
inside the instrument. Second, the   measured pressure 
falls steadily from spot A to H (Figs. S3 and S15 of 
Supporting  Information),  since  the  vacuum  pump 
continues  to  run  while  the  instrument  scans  each 
spot. We tested linear models incorporating spot posi-
tion (categorical) and pressure (continuous) to pre-
dict the offset. When used separately, both pressure 
(P = 0.1236) and spot position (P = 0.998) failed to 
predict the offset; and failed to predict the multiplier.
There were significant differences in offset between 
arrays (Fig. 1), which might be attributable to differ-
ences in arrays, in the instruments from week to week, 
or in the sample preparation protocol and scanning 
from laboratory to laboratory. We used a linear mixed-
effects model to estimate these variances.47
 Y ijkl = µ + Lj + Wk + Cjkl + Eijkl  (1.1)
We write Yijkl for the alignment offset, or multiplier. 
Here i = 1, …, 8 ranges over the spots, j = 1, …, 5 ranges 
over laboratories, k = 1, …, 6 ranges over weeks, and 
l = 1,2 ranges over the duplicate arrays used each week 
in each laboratory. The term µ represents the overall 
mean of Y; other terms represent random effects. We let 
Lj~N(0,σL
2), Wk~N(0,σW
2), Cjkl~N(0,σC
2) and Eijkl~N(0,σE
2) 
represent the laboratory, week, array effects and resid-
ual error (unexplained spot-to-spot variability within a 
array), respectively. All random effects were assumed 
to be independent. All the confidence intervals for the 
estimates overlap (Table 1); all of the variance sources 
are of comparable importance. The best point estimates 
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Figure 1. A) Alignment offsets by ProteinChip. The arrays on the x-axis 
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suggest that lab-to-lab and array-to-array variability in 
the alignment offset are likely to be larger than week-to-
week variability. The same applies to the Multiplier.
Alignment variability on a single 
instrument
For  spectra  scanned  on  the  common  instrument, 
both pressure (P = 6.033 × 10−6) and spot position 
(P = 2.196 × 10−8) were significant predictors of the 
offset. Spot position remained significant if pressure 
was already included in the model (P = 0.00015), but 
pressure became insignificant if added to a model that 
already included spot position (P = 0.6413). We only 
include a spot factor to explain the offset.
Similarly,  there  were  significant  differences  in 
offset between arrays for the spectra on the   common 
instrument  (Fig.  S8  of  Supporting  Information). 
Each term was significant by fitting the mixed-effect 
  models. The best point estimates (Table S1 of Sup-
porting  Information)  suggest  that  spot-to-spot  and 
array-to-array variability are larger than the variability 
attributable to running samples prepared in   different 
laboratories during different weeks.
reproducibility of intensities in aligned 
spectra across instruments
We  computed  the  mean  spectrum  by  averaging  the 
intensities at each time point.45 Peaks of the mean spec-
tra were higher and narrower after   alignment (Figs. S4 
and  S16  of  Supporting  Information). We  computed 
the standard deviation (SD) and coefficient of varia-
tion (CV) at each time point (Fig. 2 and Fig. S9 of 
Supporting Information). SD appeared to be roughly 
proportional to the mean spectral intensity. However, 
SD was relatively greater at the locations of the most 
prominent peaks; this added variability is due in part 
to additional variation in the peak locations that is not 
fully accounted for by the offsets used to align the spec-
tra globally. Away from the peaks, the CV follows a 
simple pattern. The first 20 µs (about 2860 Daltons/
charge)  were  discarded,  since  there  was  substantial 
matrix noise and saturation for most spectra. From 20 
to 25 µs (about 4500 Daltons/charge), it is still the noise 
region that tends to be highly variable, with CVs reach-
ing 90%. The CV then declines until about 40 µs (11500 
Daltons/charge), where it stabilizes at around 25%.
reproducibility of intensities in aligned 
spectra on a single instrument
For spectra on the common instrument, during the initial 
period of about 5 µs (214 Daltons/charge, the approxi-
mate time when the ionized matrix molecules reach 
the detector), the spectra are highly reproducible, with 
CV under 5%. From 5 to 15 µs (about 1545 Daltons/
charge), there is a large matrix noise region that tends 
to be highly variable, with CVs reaching 50%. From 
here until 30 µs (6150 Daltons/charge), the base CV 
is near 20%. The CV then declines until about 50 µs 
(17160 Daltons/charge), where it stabilizes below 5%. 
From these results, the main variability sources in the 
spectra are the huge differences in baseline caused by 
the matrix noise, with additional spikes of variability 
from large peaks that are not perfectly aligned.
reliability of peak localization  
across instruments
The occurrence of a maximum at the end of an inter-
val suggests the interval may not contain a true peak. 
So, for each peak, we modeled the distribution of the   
relative locations across spectra as a beta   distribution, 
Table 1. Components of variance explaining the alignment offset and the multiplier.
Random  
effect
Offset Multiplier
standard deviation 
(nanoseconds)
95% confidence 
interval
% variance 
explained
standard 
deviation 
95% confidence 
interval
% variance 
explained
Lab σL = 16.69 (8.55, 32.60) 50.07 σL = 3.10 × 10−4 (1.21 × 10−4, 
8.13 × 10−4)
12.51
Week σW = 2.74 (0.42, 17.73) 1.35 σW = 5.77 × 10−8 NA 0.00
Array σC = 15.28 (12.32, 18.96) 41.96 σC = 7.20 × 10−4 (5.80 × 10−4, 
8.89 × 10−4)
65.55
Spot 
(residual)
σE = 6.07 (5.66, 6.52) 6.62 σE = 4.20 × 10−4 (3.97 × 10−4, 
4.58 × 10−4)
22.30Diao et al
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Beta  (α,  β);  parameters  α  and  β  are  fit  using  the 
method of moments. A peak was “questionable” if 
both α , 1 and β , 1, since this ensured the distri-
bution was concentrated at the ends of the interval. 
Otherwise, the peak was “reliable”.
We  found  53  questionable  peaks  and  237  reli-
able  peaks  in  the  spectra  collected  from  different 
instruments. The questionable peaks tended to be nar-
rower and lower. The median width of intervals con-
taining questionable or reliable peaks was 8τ or 17τ, 
respectively.  The  median  height  of  questionable  or 
reliable peaks was 157 or 295, resp. The heights of 
the  questionable  peaks  usually  had  slightly  higher 
CVs than other peaks occurring in similar portions of 
the spectrum. All questionable peaks occurred during 
the first 40 µs, which corresponds to the exponentially 
decaying part of the spectra, plus the first two clusters 
of dominant peaks. We retained the reliable peaks for 
further analysis.
reliability of peak localization  
on a single instrument
On the common instrument, we found 106 question-
able peaks and 477 reliable peaks; the increase in the 
number of peaks is likely attributable to the higher 
resolution of the common instrument. The median width 
of questionable or reliable peaks was 9τ or 37τ, resp., 
and the median height was 282 or 411, resp. A majority 
of the questionable peaks occurred: i) between 10 and 
12 µs, ii) between 19 and 20 µs, and iii) between 26 
and 30 µs. The first portion occurs at the beginning of 
the sharp rise in the matrix noise region; the other two 
occur as the matrix noise region is coming to an end, 
on either side of a cluster of prominent peaks.
reproducibility of peak heights  
across instruments
After quantifying the heights of reliable peaks, we 
computed the CV for each peak (Figs. S1 and S13 of 
Supporting Information). The median CV was 72%, 
with inter-quartile range IQR = 10.41%. The CV was 
similar  for  most  peaks.  However,  there  is  a  slight 
drop in CV around t = 40 µs. Having a nearly constant 
CV suggests that the SD is roughly proportional to 
the mean. After log-two transformation, the median 
CV = 1.25% with IQR = 1.6%.
After log transformation, we used Equation (1.1) to 
construct a separate random-effects model for each peak. 
The random effects have the same interpretation, but 
Yijkl denote the logarithmic peak height. At most peaks, 
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the lab-to-lab differences make the largest contribution 
to the total variance, between 60% and 80%. Week-to-
week and array-to-array variation contribute about 10%, 
and residual contribute about 20% (Fig. 3). Overall, lab 
and array variation dominate the total variance.
reproducibility of peak heights  
on a single instrument
For spectra scanned on the common   instrument, the 
median  CV  was  33%,  with  IQR  =  8.46%. The  CV 
was similar for most peaks after reaching the maxi-
mum in the matrix noise region at around 10 µs. After 
log-two transformation, the median CV = 6.1% with 
IQR = 1.7%. At most peaks, the residual or   spot-to-spot 
variability made the largest contribution, between 40% 
and 60%.   Week-to-week and   array-to-array   differences 
contribute about 20%; lab-to-lab differences contribute 
less than 10% (Fig. S10 of   Supporting Information). At 
both ends of the spectrum, however, the array-to-array 
variance dominates the spot-to-spot variance. Overall, 
spot and array effects are at least as large as week and 
laboratory effects.
The impact of normalization  
on reproducibility of peak heights  
across instruments
We  globally  normalized  the  log-transformed  data 
within each spectrum by subtracting the mean log peak 
height for that spectrum. This procedure   substantially 
reduced the variance in peak heights, from a median 
variance of 0.8177 before to 0.195 after normaliza-
tion (Fig. 4). After normalization, we repeated the 
peak-  by-peak variance analysis described previously 
(Fig. 5 and Fig. S12 of   Supporting   Information). The 
contribution  of  week-to-week  differences  is  nearly 
zero. In general, the contribution of   lab-to-lab differ-
ences was decreased substantially, while   array-to-array 
stayed about the same. For most peaks, nearly all the 
remaining  variability  arises  from  the  spot-to-spot 
differences.
The impact of normalization on 
reproducibility of peak heights  
on a single instrument
On  the  common  instrument,  the  same  procedure 
reduced  the  peak  height  variance  from  0.243  to 
0.117  (Fig.  S11  of  Supporting  Information).  The 
  week-to-week differences contribution is also nearly 
zero. In general, the percent of variance attributable 
to array differences was decreased, while lab-to-lab 
stayed about the same. For most peaks, nearly all 
the  remaining  variability  arises  from  the  residual 
  spot-to-spot differences.
Discussion
In  2005,  the  Early  Detection  Research  Network 
(EDRN)  conducted  the  first  study  to  assess  the 
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reproducibility  of  SELDI  spectra.29  They  reported 
that frequent and accurate calibrations were essential 
for reproducibility. While we agree with the EDRN’s 
assessment, we find that alignment of spectra (with-
out calibration) is adequate for reproducibility. In the 
present  study,  we  found  that  the  offsets  required 
to  align  the  spectra  correctly  were  on  the  order 
of −10τ to +20τ, where τ = 4 nanoseconds was the 
time   resolution of the instrument. An analysis of the 
  variability in the offset showed that the lab-to-lab and 
array-to-array variability was at least as large as the 
variability attributable to spot differences or different 
weeks when the experiments were performed. When 
the spectra were prepared in different laboratories but 
scanned on the same instrument, the offsets required to 
align the spectra correctly were on the order of ±10τ, 
where τ = 2 nanoseconds was the time resolution of 
the instrument. Moreover, part of this offset could be 
explained by a fixed spot effect arising from the dif-
ferent spot positions. An analysis of the remaining 
variability in the offset showed that the spot-to-spot 
and array-to-array variability was at least as large as 
lab-to-lab or week-to-week variability. When spectra 
are  scanned  on  different  instruments,  those  instru-
ment  differences  are  larger  than  differences  over 
time. When spectra are merely prepared by different 
laboratories but scanned on a common instrument, 
the differences in alignment due to preparation using 
a standard protocol appear to be relatively small.
The EDRN based their assessment of the repro-
ducibility on only three peaks, the largest and most 
prominent peaks in their samples, and concluded that 
the largest peaks had the best chances of being repro-
ducible.28 Our study investigated the variability in all 
237 peaks that we were able to detect in our spectra. 
Our approach yields a much more detailed picture of 
the reproducibility of the spectra as a whole, which 
we believe will be important when trying to use low 
intensity peaks as markers to distinguish between dif-
ferent disease states. In addition, this study included 
an analysis of spectra collected on the same physi-
cal instrument, whereas the EDRN study only used 
data  from  different  instruments.  By  restricting  our 
attention to spectra collected on a single instrument, 
we were able to assess the variability inherent in the 
  sample preparation protocol, without confounding that 
  variability with differences between instruments.
The EDRN found that the CV of the peak height (or 
intensity) ranged between 9% and 41%. This result is 
comparable to our findings on a common instrument, 
where the median CV of peaks in unnormalized spec-
tra was 33%. Johnson and colleagues48 reported that 
the median CV for “ion abundance” of peaks was also 
around 30% on an extremely high-resolution Fourier-
transform mass spectrometer. It is conceivable that a 
CV of around 30% is inherent in the technology that 
is being used to extract ions from samples, regardless 
of how the abundance of those ions is later measured 
in a mass spectrometer. Our study also assessed the 
differences between instruments. We found slightly 
higher CVs point-wise for all time points in the spec-
trum, as well as for the heights of individual peaks, 
where the median CV in unnormalized spectra was 
72%. Normalization reduced the CV of peak heights 
to  18%–20%  both  on  a  common  instrument  and 
across  different  instruments.  Studies  using  various 
quality  control  methodologies  have  reported  CV’s 
in this range. For example, Hong used a correlation 
matrix  tool  to  exclude  outlier  spectra,  resulting  in 
CV’s ~20%.49 Normalization using total ion current 
resulted in CV’s of 15%–20%.50 Forshed et al used 
a combination of PCA to exclude outlier spectra as 
well as peak normalization to obtain CV’s between 
10%–20%.51
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We extended the EDRN analyses by decomposing 
the  variance  at  each  peak.  Our  main  goal  was  to 
determine which variability source gave the greatest 
contribution: 1) differences in the array preparation by 
user and spectra generation on different instruments, 
2)  differences  in  the  individual  instruments  from 
  week-to-week,  3)  differences  between  ProteinChip 
arrays,  or  4)  differences  between  individual  spots 
on  the  ProteinChip  arrays.  Before  normalization, 
  differences  between  labs  accounted  for  the  largest 
portion of   variability, and differences between spots 
were  second. After  normalization,  the  contribution 
of lab-to-lab differences was substantially reduced. 
Similarly, the EDRN prostate cancer reproducibility 
study  demonstrated  that  intralaboratory  variability 
was comparable to interlaboratory variability (range 
of  intralaboratory  CV’s  of  the  three  peaks  was 
16%–43%,  9%–23%,  and  11%–20%,  respectively 
where as the range of interlaboratory CV’s of the three 
peaks was 36, 17, and 15%, respectively).29 In that 
study,  the  normalization  process  within  the  Pro-
teinChip software was used. In our study, normaliza-
tion also reduced the total variance in peak heights by 
about 75%. Interestingly, the percentage of variance 
explained  by  array-to-array  variation  stayed  about 
the same. This suggests that normalization alone is 
adequate to remove the variability arising from scan-
ning the arrays prepared by different researchers on 
different instruments.
For  the  analysis  of  arrays  scanned  on  a  single 
instrument, our main goal was to determine which 
of the four sources of variability contributes most: 
1)   differences in the sample preparation protocol in dif-
ferent laboratories; all other three are same as above. 
Both  before  and  after  normalization,  differences 
between spots accounted for the largest portion of vari-
ability, and differences between arrays were   second. 
This suggests that most of the variability observed in 
this study is inherent in the surface chemistry on the 
array spots that first binds proteins and then releases 
ions. Normalization also reduced the total variance in 
peak heights by about half. Before normalization, dif-
ferences in the instrument settings from   week-to-week 
were about the same size as array differences. After 
normalization, these week-to-week differences virtu-
ally disappeared. This finding provides strong evidence 
that a simple global normalization can successfully 
correct for almost all the differences due to changes 
in the instrument, at least over a period of six weeks. 
The percentage of variation caused by array differ-
ences also declined after normalization.   Interestingly, 
the  percentage  of  variance  explained  by  different 
laboratories stayed about the same, in contrast to the 
effect of normalization on spectra collected on differ-
ent instruments. However, the amount of variation due 
to laboratory preparation in the setting of a common 
instrument started out smaller than the amount due 
to the combination of laboratory preparation and dif-
ferent instruments in the multi-instrument part of the 
analysis. Moreover, the final percentage of variance 
explained by laboratories differences was about the 
same in the common instrument and   multi-instrument 
situations after normalization. This finding, together 
with the fact that the absolute amount of variance after 
normalization is similar in the two studies suggests 
that our normalization procedure can correct for dif-
ferences between instruments, but that there are some 
intrinsic differences in individual sample preparation 
that cannot be removed simply by normalization. This 
further suggests that some improvement in reproduc-
ibility might be obtained by switching from manual to 
robotic preparation.
Lastly, the use of wavelets in analyzing mass spec-
tra has been shown to improve peak detection and 
classification. For example, Du et al demonstrate that 
their wavelet procedure identifies more peaks (both 
large and small) while maintaining an acceptable false 
discovery rate.
52 An advantage of the wavelet method 
is that no baseline subtraction is required, eliminating 
a step that can induce variable results depending on 
the parameters used.
Experiments  that  are  intended  to  discover  bio-
markers that distinguish between disease states must 
use designs that avoid confounding the contrast of 
interest with experimental factors such as run order 
or  laboratory.  However,  with  proper  experimental 
design and data processing, we have demonstrated 
that the SELDI ProteinChip system is a reproducible 
technology that can be used reliably for discovery of 
biomarkers both over time and between laboratories.
Acknowledgements
This research was funded in part by NIH/NCI grants P30 
CA016672,  P01  CA106451-01,  R01  CA107304-02, 
P50 CA070907-05 and the M.D. Anderson Ovarian 
SPORE P50 CA083639-10.Diao et al
54  Cancer Informatics 2011:10
Dr. Bast serves on the Scientific Advisory Board 
of Vermillion Diagnostics.
Abbreviations
EDRN,  Early  Detection  Research  Network;  FBS, 
Fetal Bovine Serum; IQR, inter-quartile range; SOP, 
standard operating procedure; UDWT, undecimated 
discrete wavelet transform.
Disclosure
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
  consideration by any other publication and has not 
been  published  elsewhere.  The  authors  and  peer 
reviewers of this paper report no conflicts of inter-
est. The authors confirm that they have permission to 
reproduce any copyrighted material.
References
  1.  Tumblin A, Tailor A, Hoehn, et al. Apolipoprotein A-I and serum amyloid a 
plasma levels are biomarkers of acute painful episode in patients with sickle 
cell disease. Haematologica. April 7 2010. [Epub ahead of print].
  2.  MacGregor G, Gray RD, Hilliard TN, et al. Biomarkers for cystic fibrosis 
lung disease: application of SELDI-TOF mass spectrometry to BAL fluid.   
J Cyst Fibros. 2008 Sep 7;(5):352–8.
  3.  Yang S, Xu L, Wu HM. Rapid multiplexed genotyping for hereditary throm-
bophilia by SELDI- TOF mass spectrometry. Diagn Mol Pathol. Mar 2010; 
19(1):54–61.
  4.  De Young LX, Bella AJ, O’Gorman DB, Gan BS, Lim KB, Brock GB. 
Protein biomarker analysis of primary Peyronie’s disease cells. J Sex Med.   
Jan 2010;7(1 Pt 1):99–106.
  5.  Simonsen AH, McGuire J, Podust VN, et al. Identification of a novel panel 
of cerebrospinal fluid biomarkers of Alzeheimer’s disease. Neurobiol Aging. 
Jul 2008;29(7):961–8.
  6.  Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of 
thrombotic  thrombocytopenic  purpura  uing  surface  enhanced  laser 
  desorption/ionization  time-of-flight  (SELDI-TOF)-mass  spectrometry. 
J Thromb   Haemost. Feb 2006;4(2):333–8.
  7.  Wilson AM, Kimura E, Harada RK, et al. β2-Microglobulin as a biomarker 
in  peripheral  arterial  disease:  proteomic  profiling  and  clinical  studies. 
  Circulation. Sep 18 2007;116(12):1396–403.
  8.  Fan Y, Wang  J, Yang Y,  et al.  Detection  and  identification of  potential 
  biomarkers of breast cancer. J Cancer Res Clin Oncol. Mar 17 2010. [Epub 
ahead of print].
  9.  Shi  L,  Zhang  J,  Wu  P,  et  al.  Discovery  and  identification  of  potential 
  biomarkers  of  pediatric  acute  lymphoblastic  leukemia.  Proteome  Sci.   
Mar 16 2009;7:7.
  10.  Caron J, Mange A, Guillot B, Solassol J. Highly sensitive detection of 
melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol.   
Sep 2009;135(9):1257–64.
  11.  Wei YS, Zheng YH, Liang WB, et al. Identification of serum biomarkers 
for nasopharyngeal carcinoma by proteomic analysis. Cancer. Feb 1 2008; 
112(3):544–51.
  12.  Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic 
patterns in diagnosis of lung cancer. BMC Cancer. Jul 20 2005;5:83.
  13.  Lu HB, Zhou JH, Ma YY, et al. Five serum proteins identified using SELDI- 
TOF-MS  as  potential  biomarkers  of  gastric  cancer.  Jpn  J  Clin  Oncol.   
Apr 2010;40(4):336–42.
  14.  Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum 
proteomic analysis for the detection of early stage ovarian cancer. Cancer 
Res. Aug 15 2004;64(16):5882–90.
  15.  Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomark-
ers of papillary thyroid carcinoma. Mol Cancer. Sep 28 2009:8–79.
  16.  Liu  M,  Li  CF,  Chen  HS,  et  al.  Differential  expression  of  proteomics 
  models of colorectal cancer, colorectal benign disease and healthy controls. 
  Proteome Sci. Mar 25 2010;8(1):16.
  17.  Saito Y, Oba N, Nishinadagawa S, et al. Identification of beta2-   microgloblin 
as  a  candidate  for  early  diagnosis  of  imaging-  invisible  hepatocellular 
  carcinoma  in  patient  with  liver  cirrhosis.  Oncol  Rep.  May  2010;23(5): 
1325–30.
  18.  Kakehashi A, Kato A, Inoue M, et al. Cytokeratin 8/18 as a new marker 
of mouse liver preneoplastic lesions. Toxicol Appl Pharmacol. Jan 1 2010; 
242(1):47–55.
  19.  Guo J, Wang W, Liao P, et al. Identification of serum biomarkers for pancre-
atic adenocarcinoma by proteomic analysis. Cancer Sci. Dec 2009;100(12): 
2292–301.
  20.  Vermaat JS, Vander Tweel I, Mehra N, et al. Two-protein signature of novel 
serological markers apolipoprotein-A1 and serum amyloid alpha predicts 
prognosis in patients with metastatic renal cell cancer and improves the 
  currently used prognostic survival models.
  21.  Bouamrani A, Ramus C, Gay E, et al. Increased phosphorylation of vimentin 
in noninfiltrative meningiomas. PLoS One. Feb 16 2010;5(2):e9238.
  22.  Al-Ruwaili JA, Larkin SE, Zeidan BA, et al. Discovery of serum protein 
biomarkers for prostate cancer progression by proteomic analysis. Cancer 
Genomics Proteomics. Mar–Apr 2010;7(2):93–103.
  23.  Han M, Liu Z, Yu J, Zheng S. Identification of candidate molecular   markers 
predicting  chemotherapy  resistance  in  non-small  cell  lung  cancer.  Clin 
Chem Lab Med. Mar 26 2010. [Epub ahead of print].
  24.  He J, Shen D, Chung DU, et al. Tumor proteomic profiling predicts the 
  susceptibility of breast cancer to chemotherapy. Int J Oncol. Oct 2009;35(4): 
683–92.
  25.  Dalenc F, Doisneau-Sixou SF, Allal BC, et al. Tipifarnib plus tamoxifen 
in  tamoxifen-resistant  metastatic  breast  cancer:  a  negative  phase  II  and 
  screening  of  potential  therapeutic  markers  by  proteomic  analysis.  Clin 
  Cancer Res. Feb 15 2010;16(4):1264–71.
  26.  Petrik V, Saadoun S, Loosemore A, et al. Serum alpha 2-HS glycoprotein 
predicts survival in patients with glioblastoma. Clin Chem. Apr 2008;54(4): 
713–22.
  27.  Grizzle  WE,  Semmes  OJ,  Basler  J,  et  al.  The  early  detection  research 
  network surface-enhanced laser desorption and ionization prostate cancer 
detection study: A study in biomarker validation in genitourinary oncology.
  28.  McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF whole serum   proteomic 
profiling with IMAC surface does not reliably detect prostate cancer. Clin 
Chem. Jan 2008;54(1):53–60.
  29.  Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein   profiling 
by surface-enhanced laser desorption/ionization time-of-flight mass spec-
trometry for the detection of prostate cancer: I. Assessment of platform 
reproducibility. Clin Chem. Jan 2005;51(1):102–12.
  30.  Linke T, Doraiswamy S, Harrison EH. Rat plasma proteomics: effects of 
abundant protein depletion on proteomic analysis. J Chromatogr B Analyt 
Technol Biomed Life Sci. Apr 2007 15;849(1–2):273–81.
  31.  Andersen  JD,  Boylan  KL,  Xue  FS,  et  al.  Identification  of  candidate 
  biomarkers in ovarian cancer serum by depletion of highly abundant   proteins 
and  differential  in-gel  electrophoresis.  Electrophoresis.  Jan  2010;31(4): 
599–610.
  32.  Orvisky E, Drake SK, Martin BM, et al. Enrichment of low molecular 
weight fration of serum for MS analysis of peptides associated with hepato-
cellular carcinoma. Proteomics. May 2006;6(9):2895–902.
  33.  Zhou J, Trock B, Tsangaris RN, et al. A unique proteolytic fragment of 
alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast 
Cancer Res Treat. Nov 10 2009. [Epub ahead of print].
  34.  Jansen C, Hebeda KM, Linkels M, et al. Protein profiling of B-cell lympho-
mas using tissue biopsies: A potential tool for small samples in pathology. 
Cell Oncol. 2008;30(1):27–38.reproducibility of SeLDI spectra
Cancer Informatics 2011:10  55
  35.  Ward DG, Nyangoma S, Joy H, et al. Proteomic profiling of urine for the 
detection of colon cancer. Proteome Sci. Jun 16 2008;6:19.
  36.  Shirai Y, Sogawa K, Yamaguchi T, et al. Protein profiling in pancreatic juice 
for detection of intraductal papillary mucinous neoplasm of the pancreas. 
Hepatogastroenterology. Sep–Oct 2008;55(86–87):1824–9.
  37.  Melle  C,  Ernst  G,  Winkler  R,  et  al.  Proteomic  analysis  of  human 
papillomavirus-related  orgal  squamous  cell  carcinoma:  identifica-
tion  of  thioredoxin  and  epidermal-fatty  acid  binding  protein  as  upregu-
lated  protein  markers  in  microdissected  tumor  tissue.  Proteomics.  Apr 
2009;9(8):2193–201.
  38.  Sun W, Ye Z, Mi Z, Shi T, Han C, Guo S. A comparative study on proteomics 
between LNCap and DU145 cells by quantitative detection and SELDI 
analysis. J Hauzhong Univ Sci Technolog Med Sci. Apr 2008;28(2):174–8.
  39.  Shintani S, Hamakawa H, Ueyama Y, Hatori M, Toyoshima T. Identification 
of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell 
carcinoma using the SELDI ProteinChip platform. Int J Oral Maxillofac 
Surg. Jan 2010;39(91):68–74.
  40.  Albrethsen J, Bøgebo R, Olsen J, Raskov H, Gammeltoft S. Preanalytical 
and  analytical  variation  of  surface-enhanced  laser  desorption-ionization 
time-of-flight mass spectrometry of human serum. Clin Chem Lab Med. 
2006;44(10):1243–52.
  41.  Timms JF, Arslan-Low E, Gentry-Maharaj A, et al. Preanalytic influence 
of  sample  handling  on  SELDI-TOF  serum  protein  profiles.  Clin  Chem.   
Apr 2007;53(4):645–56. [Epub Feb 15 2007].
  42.  Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of Human Proteome Orga-
nization Plasma Proteome Project (HUPO PPP) reference specimens using 
surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) 
mass spectrometry: multi-institution correlation of spectra and identifica-
tion of biomarkers. Proteomics. Aug 2005;5(13):3467–74.
  43.  Liggett WS, Barker PE, Semmes OJ, Cazares LH. Measurement reproduc-
ibility  in  the  early  stages  of  biomarker  development.  Disease  Markers. 
2004;20:295–307.
 44.  Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, Kuerer HM. 
Improved peak detection and quantification of mass spectrometry data acquired 
from surface-enhanced laser desorption and ionization by denoising spectra   
with  the  undecimated  discrete  wavelet  transform.  Proteomics.  2005;5: 
4107–17.
  45.  Morris JS, Coombes KR, Koomen JM, Baggerly KA, Kobayashi R. Feature 
extraction and quantification for mass spectrometry in biomedical applica-
tions using the mean spectrum. Bioinformatics. 2005;21:1764–75.
  46.  R Development Core Team. R; A language and environment for statistical 
computing. Vienna, R Foundation for Statistical Computing, 2004. ISBN 
3-900051-07-0.
  47.  Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus, New York, 
Springer-Verlag, 2000. ISBN 0-387-98957-0.
  48.  Johnson  KL,  Mason  CJ,  Muddiman  DC,  Eckel  JE.  Analysis  of  the 
low  molecular  weight  fraction  of  serum  by  LC-dual  ESI-FT-ICR  mass 
  spectrometry: precision of retention time, mass, and ion abundance. Anal 
Chem. 2004;76:5097–103.
  49.  Hong H, Dragan Y, Epstein J, et al. Quality control and quality assessment 
of data from surface enhanced laser desorption/ionization (SELDI) time of 
flight (TOF) mass spectrometry. BMC Bioinformatics. 2005;6(Suppl 2):S5.
  50.  Semmes OJ, Cazares LH, Ward MD, et al. Discrete serum protein signatures 
discriminate between human retrovirus associated hematologic and neuro-
logic disease. Leukemia. 2005;19:1229–38.
  51.  Forshed  J,  Pernemalm  M,  Seng  Tan  C,  et  al.  Proteomic  data  analysis 
  workflow for discovery of candidate biomarker peaks predictive of   clinical 
outcome for patients with acute myeloid leukemia. J Proteome Res. 2008; 
7(6):2332–41.
  52.  Du  P,  Kibbe W,  Lin  S.  Improved  peak  detection  in  mass  spectrum  by 
  incorporating  continuous  wavelet  transform-based  pattern  matching. 
  Bioinformatics. 2006;22(17):2059–65.Diao et al
56  Cancer Informatics 2011:10
supplimentary data: 
Protocol for FBS Serum Profiles  
for Qc
MDACC Multi Instrument Optimization, 
Normalization and QC Project
Materials provided by Ciphergen:
•  Single Use Serum Aliquots: Fetal Bovine Serum, 
Heat Inactivated, Cat # 16140-063, Invitrogen-Life 
Technologies.
•  200 µl U9 aliquots (use 2 times, always refreeze 
at −20).
•  CM10 arrays-prepare 2 arrays each week (at same 
time).
•  CM10 binding/wash buffer-store at 4 °C: aliquot 
into 10 ml test tube for each use.
•  2 bioprocessor reservoirs (You will use two columns 
for each prep, save the reservoir and use different 
columns each time).
•  NP20 array (use for calibrants).
•  SPA—prepare  a  fresh  tube  of  SPA  each  week: 
200 µl Acetonitrile (100%) + 200 µl of 1% TFA 
(also made fresh weekly!), vortex well for sev-
eral minutes by taping the tube onto a vortex and 
let it mix continuously. Spin at 10000 rpm/2 min. 
Remove 200 µl (without touching bottom) into a 
fresh tube. Store in the dark until use.
○  1% TFA: 100 ul + 10 mls of ddH20: (add TFA 
in fume hood).
•  All in One Protein Calibrants. Prepare   according 
to insert directions. Store diluted aliquots at -20 
°C. Collect a new spectrum each week. (Can use 
same array over again). Add 5 ul of SPA to the 5 ul 
  aliquot of calibrants and spot 1 ul onto each spot of 
a NP20 chip. Keep prepared chip in the dark.
Weekly array preparation
1. Thaw one serum and one U9 aliquot. Make sure 
U9 is completely thawed. Vortex well.
2. Centrifuge serum at 10000 rpm/10 min/4 °C.
3. Add 30 µl of U9 to a fresh 1.5 ml tube.
4. Add 20 µl of the centrifuged serum to the U9 = total 
of 50 µl.
5. Incubate with gentle shaking at 4 °C/20 minutes. 
Try to keep this time as consistent as possible.
6.   While serum is incubating at 4 °C, set up a biopro-
cessor with 2 CM10 arrays. Make sure the gasket 
doesn’t cover the spot.
  7.   Pre-wet spots with 150 µl buffer/spot. Incubate 
with shaking/5 min/RT.
  8. Remove and repeat buffer pre-wetting.
  9.   Add 1450 µl of the binding buffer to the serum/
U9  mixture  (final  1:75  dilution  of  the  serum). 
Invert to mix well.
10.   Remove final buffer wash from arrays and add 50 ul 
of diluted serum/well. Watch for airbubbles!
11.    Cover wells (can use 96 well plate sealer). Shake 
at RT for 30 minutes. (If using a robot mixer, use 
Form = 48, amp = 9)
12. Remove samples.
13.   Add  150  µl  of  buffer/well.  Shake  5  min/RT. 
Remove.
14. Repeat 2 X for a total of 3 washes with mixing.
15.   Add 150 µl of ddH20. Remove (no incubation). 
Repeat.
16.   Quickly remove reservoir and wick off excess 
water from spots.
17. Let dry 5 min. Keep this time consistent!
18. Add 1 µl SPA/spot. Let dry. Repeat.
19. Read within next hour.
Working order to get arrays prepared  
in approx. 1½ hours
1. Quick cool centrifuge to 4 °C if necessary.
2. Take serum and U9 aliquot from freezer.
3. Thaw serum in your hand quickly, mix gently and 
begin centrifugation.
4. Hold U9 in hand until it is thawed. Mix well.
5. Set up bioprocessor with the 2 arrays.
6. During the U9/serum incubation, begin the buffer 
prewashes of the arrays.
7. During sample incubation on the arrays, prepare 
SPA.
Database
Always save spectra into the database specified as the 
“QC project”. The user should be set to ‘QC’. Keep 
all calibration spectra in a ‘Calibration’ project folder. 
Create a new project file each week to for saving the 
weekly files.
Calibration
Average 100 spectra from a spot with the All in One 
Protein II calibrants, manual or with a spot protocol. Be 
sure the intensity and sensitivity values that you specify 
don’t cause any of the peaks to go off scale. Use the reproducibility of SeLDI spectra
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same intensity/detector sensitivity settings each time 
you create a calibration spectrum for the most consis-
tency. Most calibrant -containing spots will last several 
weeks and can be read over and over. If you need to 
increase the laser intensity alot to acquire the same cali-
brants peaks, then it is time to make a new chip.
Internally  calibrate  using  the  masses:  12230, 
16951 and 29023. Save spectra. Set as default instru-
ment  calibration  equation.  Collection  protocol: 
high mass = 50,000; optimize from 12,000–30,000 
  daltons; pulse settings—center; if you have a IIc, set 
the deflector to 5000 daltons.
Creating spectrum labels
Go  to  Options,  choose  “Configure  dynamic  spec 
tags”: make sure box is checked for adding to spectra 
as they are acquired. Add to tag: 1) Spot #, 2) Sample 
Name, 3) Sample Group.
When you enter a barcode, go to File, Open chips, 
and  choose  ‘new’. Add  barcode. Then type in  the 
information below in the correct spaces.
Sample Name =   QC_1 (for first week, then change 
it to 2, etc).
Sample Group = the PI’s name (ie, Bast).
Sample Type = FBS (not included in the spectral tag).
Spectrum acquisition
LMW spot: high mass to acquire; 50,000 daltons; opti-
mization  range  =  1,000  to  30,000  daltons;  time  lag 
focus- set to 700 ns; IIc deflector- set to 1000 daltons; 
set warming shots to collect 1 at the same intensity that 
you choose for all data collection, but don’t use warming 
shots; collect from 20 to 80 with 10 shots/area, delta 5.
HMW spot: high mass to acquire; 200,000   daltons; 
optimization range = 30,000–150,000 daltons; time lag 
focus- center; IIc deflector- set to 10,000 daltons; set 
warming shots to collect 1 at the same intensity that you 
choose for all data collection, but don’t use warming 
shots; collect from 23 to 78 with 10 shots/area, delta 5.
Variables that will most affect spectrum
•  Calibration equation: For this study, always use a 
curve based on 12230, 16951 and 29023 daltons 
(for both LMW and HMW spectra).
Settings adjusted within spot protocol
•  Laser Intensity:
•  Detector Sensitivity:
•  Time lag focus:
○  LMW: use 700 ns
○  HMW: center of optimization range between 
30,000 and 150,000 daltons.
Settings adjusted outside  
of spot protocol
•  Voltage Detector: check setting and record in your 
notes: to access this setting, go to Instrument, con-
figuration, in bottom section see Detector = PBSII-
(1800 to 2200 V); IIc-(2700 to 3000 V). If you start 
to lose low intensity peaks from the spectrum, the 
detector voltage may need to be increased (use 50 
unit increases).
•  Laser Focus (service engineer will change this if 
needed): If any of the peak shapes change (ie, poor 
resolution), focusing the laser can help optimize 
resolution.
Read the spots with both a low mass acquisition spot 
protocol and a high mass acquisition spot   protocol. 
The above listed variables should be adjusted so that 
you collect a QC spectrum that gives a peak pattern 
as closely resembling the ‘QC standard’ (spectrum 
saved on your computer) as possible.
First, read spots A–C and compare spectrum to the 
‘standard’ stored on your instrument. If you compare 
a spectrum to one previously acquired in the weeks 
before and it doesn’t not appear comparable, you can 
adjust the laser intensity and detector sensitivity in 
the spot protocol and read again. Then, read spots 
D–H of that chip and all 8 spots of the second chip 
you prepare each week (using a chip protocol for both 
LMW and HMW acquire). 
All chips prepared by the different labs will be read 
on one instrument to assess any preparation issues.
Specific peaks in the spectrum  
to use as a guideline
Compare the peak shape and intensity in your acquired 
spectra to the examples stored in the QC database. 
Adjust setting as required to maintain spectra integ-
rity from week to week.
LMW
Approx masses: 3984 da, 8490 da, 13.5, 15.2 and 
15.8 kD, 33.3 kD.Diao et al
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hMW
Approx masses: 33.3 kD, 66 kD, and 133 kD.
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Figure s1. Coefficient of variation of peak heights on the original raw 
scale of the data (top) and after transformation by the base-two logarithm 
(bottom).  Different  scales  are  used  on  the  vertical  axes  since  CV  is 
smaller on the log scale.
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Figure s4A. Mean spectra before (solid) and after (dashed) alignment by 
time (µs). Arrows indicate the centers of peaks that were used to optimize 
the alignment.
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Figure s2B. Alignment multiplier by the position of the spot (A–h) on 
the array.
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Figure s3. Measured pressure in the vacuum chamber by the position of 
the spot (A–h) on the array. The mean of pressure by the spots are red.
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Figure s2A. Alignment offset by the position of the spot (A–h) on the array. reproducibility of SeLDI spectra
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Figure  s4D.  Close-up  of  the  mean  spectra  before  (solid)  and  after 
(dashed) alignment in Supplemental Figure S4A, focused on the time 
period of 43 to 49 µs.
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Figure  s4B.  Close-up  of  the  mean  spectra  before  (solid)  and  after 
(dashed) alignment in Supplemental Figure S4A, focused on the time 
period of 23 to 25 µs.
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Figure  s4c.  Close-up  of  the  mean  spectra  before  (solid)  and  after 
(dashed) alignment in Supplemental Figure S4A, focused on the time 
period of 33.5 to 36 µs.
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Figure  s4e.  Close-up  of  the  mean  spectra  before  (solid)  and  after 
(dashed) alignment in Supplemental Figure S4A, focused on the time 
period of 67 to 70 µs.
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Figure s5. Coefficient of variation of peak heights. Peaks questionable 
(α , 1 and β , 1) are red.
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Figure s6A. Alignment multiplier vs. offset for different labs and weeks.Diao et al
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Figure s10. results of a peak-by-peak decomposition of variance com-
ponents  before  normalization  for  the  setting  scanned  on  a  common 
instrument. each panel shows the percentage of variance of the log-
transformed peak heights, as a function of the time-of-flight, for one of 
the factors (top left: spot; top right: array; lower left: laboratory; lower 
right: week).
C
V
0.2
0
0.8
0.6
0.4
S
D
2000
0
8000
6000
4000
M
e
a
n
 
i
n
t
e
n
s
i
t
y
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
1
2
3
0
×104
Time (microseconds)
01 02 03 04 05 06 07 08 09 0
Time (microseconds)
01 02 03 04 05 06 07 08 09 0
Time (microseconds)
Mean
01 02 03 04 05 06 07 08 09 0
Figure s9. reproducibility of spectrum intensity for the setting scanned 
on a common instrument. These graphs contain plots of the mean inten-
sity across 437 aligned spectra (top), the point-wise standard deviation 
(SD; center), and the point-wise coefficient of variation (CV; bottom) as 
functions of the time of flight.
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Figure s7. Alignment of spectrum intensity. This graphs contains the 
mean intensity across 445 spectra (blue), the mean intensity across 13 
unusual spectra with offset bigger than 100τ (red), the aligned mean 
intensity across 13 unusual spectra with offset bigger than 100τ (green) 
as functions of the time of flight.
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Figure s6B. Alignment multiplier vs. offset for different labs and weeks. 
This graph excludes the 13 unusual spectra with offset bigger than 100τ.
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Figure s12. results of a peak-by-peak decomposition of variance com-
ponents after normalization for the setting scanned on a common instru-
ment. each panel shows the percentage of variance of the log-transformed 
peak heights, as a function of the time-of-flight, for one of the factors 
(top left: spot; top right: array; lower left: laboratory; lower right: week).
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Figure s15. Measured pressure in the vacuum chamber by the   position 
of the spot (A–h) on the array for the setting scanned on a common 
  instrument. The mean of pressure by the spots are red.
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Figure s14. Alignment offset by the position of the spot (A–h) on the 
array for the setting scanned on a common instrument.
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scale of the data (top) and after transformation by the base-two logarithm 
(bottom) for the setting scanned on a common instrument. Different scales 
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Figure s16A. Mean spectra before alignment with 8τ (median offset) 
shifted (solid) and after alignment (dashed) by time (µs) for the setting 
scanned on a common instrument.
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Figure s16B. Close-up of the mean spectra before alignment with 8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental Figure S16A, 
focused on the time period of 5.5 to 9 µs.Diao et al
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Figure s16c. Close-up of the mean spectra before alignment with 8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental Figure S16A, 
focused on the time period of 12 to 14 µs.
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Figure s16D. Close-up of the mean spectra before alignment with 8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental   Figure S16A, 
focused on the time period of 24.2 to 25.2 µs.
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Figure s16e. Close-up  of  the  mean  spectra  before  alignment  with  8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental Figure S16A, 
focused on the time period of 35.15 to 35.85 µs.
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Figure s16F. Close-up of the mean spectra before alignment with 8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental   Figure S16A, 
focused on the time period of 44 to 45 µs.
69 69.5 70.5 70 71 71.5 72
2000
2100
2200
2300
2400
2500
2600
2700
2800
2900
3000
Figure s16G. Close-up of the mean spectra before alignment with 8τ 
(median offset) shifted (solid) and after alignment (dashed) by time (µs) for 
the setting scanned on a common instrument in Supplemental   Figure S16A, 
focused on the time period of 69 to 72 µs.reproducibility of SeLDI spectra
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Table s1. Components of variance explaining the alignment offset for the setting scanned on a common instrument.
Random effect standard deviation 
(nanoseconds)
95% confidence 
interval
% variance 
explained
Lab σL = 1.6164 (0.5949, 4.3916) 9.3
Week σW = 2.0608 (0.9679, 4.3876) 15.2
Array σC = 3.5024 (2.7909, 4.3952) 43.8
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